当院糖尿病内科医師 岩本・窪田らの論文が正式にpublishされました

The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
Iwamoto M, Kubota T, Sakurai Y, Wada N, Shioda S, Yamauchi T, Kadowaki T, Kubota N.
Pharmacol Res Perspect. 2022 Aug;10(4):e00971. doi: 10.1002/prp2.971.